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I

t is impossible to think about health
care today without acknowledging the
role of prescription drugs. We now
rely on drugs for treatment of the large
majority of our medical conditions. Drugs
have improved both the quality and
quantity of our lives. But, just as with
health care, policy makers are challenged
with the task of ensuring the quality,
safety, access and affordability of drugs.
To that end, legislators and government
agencies are creating new laws and
regulations and taking enforcement
actions that generate new legal issues and
work for health and food and drug
lawyers. Many faculty and students at the
University of Maryland School of Law are
involved in research, course work and
other initiatives that touch on drug laws
and policies. In this issue of the L&HCP
Newsletter, we highlight these various
activities.

Access and Affordability
The ability of drugs to combat both
acute and chronic illnesses has increased
their value among the general population,
yet the high cost of drugs has made them
unaffordable to many. The percent of the
nonelderly population without insurance
rose from 17.3% in 2002 to 17.7% in 2003
(or 44.7 million uninsured), an increase of
1.4 million over 2002. Additionally, more
than a third (36%) of Medicare beneficiaries
had no prescription drug coverage in the
fall of 2001. A 2003 Kaiser Health
Insurance Survey found that 37% of the
uninsured said they did not fill a
prescription because of cost, compared to
13% of the insured. In order to make drug
prices more affordable and thereby more
accessible, policy makers have attempted to
respond with some new and, in many cases,
highly controversial initiatives. Among
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between drugs and health law. During the past year, legal and policy issues
related to prescription drugs have consistently made headlines in the news
and the L&HCP has sponsored several forums to discuss these “hot” topics,
including panels on drug importation and compulsory licensing. The Program
also includes a number of students and faculty members who have pharmacy
backgrounds. We introduce you to them and how they have combined their
interest in pharmacy and law. Finally, a number of Program faculty members
are teaching courses or clinics and/or conducting research on drug related
issues. We highlight their teaching and scholarship.
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these is the recent passage by Congress of
a Medicare drug benefit.
On December 8, 2003, President Bush
signed into law the Medicare Prescription
Drug, Improvement, and Modernization
Act (MMA) giving seniors access to
outpatient prescription drugs. The MMA
gives seniors the choice to access this
new benefit via either a stand alone
Prescription Drug Plan (PDP) or a more
comprehensive plan under the Medicare
Advantage (MA) program. Under the
PDP, beneficiaries will pay an average
monthly premium of $35, a $250
deductible, 25% co-pay on the first $2250
spent on prescriptions and catastrophic
coverage after out-of-pocket spending
reaches $3600. Although additional
assistance is available for low-income
seniors, the bill was highly controversial as
it still leaves many seniors with significant
out-of-pocket costs and may increase
costs for some seniors if their former
employers reduce or drop their retiree
prescription drug benefits in response to
the new benefit.
These changes to the Medicare law provided
new teaching material and opportunities for
policy discussions in several L&HCP courses
such as the Seminar on Medicare and Medicaid
Fundamentals. Also, students in externships
with organizations dealing with federal health
care policy had an opportunity to learn more
about the new law. Linda Souter, a 2d year
student in the Program, writes in this issue
about her externship at BIO working with the
Director for Medicare Reimbursement and
attending meetings about the implementation of
Medicare Part D. (See story, p. 15.)
Other highly debated approaches to
reducing the costs of drugs and increasing
accessibility have included drug
importation from other countries and
compulsory licensing of patented drugs.
The passage of the MMA focused
considerable attention on the issue of
drug importation. In addition to
providing for the prescription drug
benefit, the MMA included provisions
aimed at providing lower cost drugs to
consumers. Under Section 384, the
Secretary of the Department of Health
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and Human Services (DHHS) is directed
to promulgate regulations that would
allow for the importation of prescription
drugs in certain cases. Congress
conditioned the implementation of the
MMA’s importation program on an initial
certification by the Secretary that drug
importation will pose no additional risk
to public health and safety and result in a
significant reduction in the cost of drugs
to the American consumer. As mandated
by Congress under the MMA, a DHHS
Task Force on Drug Importation
conducted a study to determine whether
importing drugs could be done at a
reasonable price without compromising
safety. The Task Force’s 135-page
report, issued in December, 2004,,
included findings that importation is
neither safe nor cost-effective. Secretary
Tommy Thompson has refused to certify
importation, and it is expected that his
successor, Mike Leavitt, will take a similar
stand.
Advocates for importation argue that
the practice introduces much needed
price competition into the marketplace
and makes drugs more affordable for U.S.
seniors, while the FDA warns that drug
importation is unsafe and illegal because
imported drugs may not meet rigorous
U.S. safety standards. Several bills were
introduced in Congress this session that
would legalize importation. Bills S. 184,
S. 334 and H.R. 700 seek to amend the
Food, Drug & Cosmetic Act with respect
to the importation of prescription drugs.
On April 7th, Senator Mike Enzi,
Chairman of the Senate Health,
Education, Labor and Pensions
Committee, announced that the Senate is
beyond debating whether to pass a drug
importation bill and has moved on to
deciding the mechanics of the bill.
Professor Tom Perez, who teaches the Law
& Health Care Program’s Access to Health
Care Clinic and who is President of the
Montgomery County Council, has been an
active advocate of drug importation. Last fall,
the L&HCP co-hosted a forum on this topic at
which Prof. Perez spoke about an initiative in
Montgomery County to establish a prescription
drug mail order program for its retirees. (For
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more on this issue, see article on the L&HCP’s
Drug Importation Forum, p. 6.)
Compulsory Licensing is also being
proposed as a mechanism by which to
provide necessary drugs at lower cost to
individuals with certain diseases. For
example, in January 2004, Essential
Inventions, a nonprofit corporation,
petitioned DHHS for compulsory licenses
to “manufacture and sell inexpensive
generic versions of latanoprost (Xalatan)
and ritonavir (Norvir).”1 The drugs are
used to treat glaucoma and HIV,
respectively, and were developed with
federal funding. Under the Bayh-Dole
Act, the government has the right to
“‘march in’ on the patent rights and license
them to another producer.”2 The NIH
turned down the request for both drugs.
Also, as a result of the anthrax scare in
fall, 2001, DHHS Secretary Tommy
Thompson sought to stockpile sufficient
amounts of ciprofloxacin (Cipro) to treat
ten million people. This amount was
significantly greater than the available
supply and Bayer, the manufacturer of
Cipro, did not have the capacity to
quickly produce such large quantities of
the drug. As a result, on October 16,
2001, Senator Schumer asked Secretary
Thompson to issue compulsory licenses
to generic manufacturers allowing them
to produce the drug.3 Thompson
declined to issue compulsory licenses
claiming that the supply of Cipro the
government was able to purchase from
Bayer was adequate to increase the
nation’s emergency reserve of antibiotics.
To learn more about the issue, on March 7,
2005, the Student Health Law Organization
(SHLO) and the Maryland Intellectual
Property Student Association co-sponsored a
forum on compulsory licensing. (For more
information about the forum, see article, p. 8.)
Threats of bioterrorism have raised a
separate set of drug access issues. After
September 11, 2001, and the anthrax scare,
the possibility of a bioterrorist attack
increased the urgency for new medicines
to prevent and treat infectious diseases.
Pharmaceutical and biotechnology
companies began working with the
government to develop and stockpile

vaccines to prevent outbreaks of such
diseases as anthrax, smallpox, plague and
others. On July 21, 2004, President Bush
signed into law Project Bioshield which
provides new tools to improve medical
countermeasures against chemical,
biological, radiological or nuclear (CBRN)
attack including the expeditious
development and licensing of vaccines.
These products must move through the
manufacturing process, pre-clinical testing,
clinical trials, and the licensing and
approval process prior to distribution.
On June 9, 2004, the L&HCP, in
collaboration with the School of Law’s Center
for Health and Homeland Security, held a

conference on “Eliminating Legal, Regulatory,
and Economic Barriers to Biodefense Vaccine
Development.” (See story, p. 16, Spring
2004 L&HCP Newsletter). The upcoming
issue of the Journal of Health Care Law &
Policy will be devoted to this topic with
contributors including Michael Greenberger,
Law School Professor and Director, Center for
Health and Homeland Security, University of
Maryland School of Law; Wendy Parmet,
Professor of Law, Northeastern University
School of Law; Gail Javitt, Policy Analyst,
Genetics and Public Policy Center, Phoebe R.
Berman Bioethics Institute, Johns Hopkins
University; Cynthia Ho, Associate Professor,
Loyola University of Chicago School of Law;
and Elin Gursky, Principal Deputy for
Biodefense, National Strategies Support
Directorate at Analytic Services, Inc.
(ANSER). To order a copy of this issue,
contact the Journal at 410-706-2115 or
jhclp@law.umaryland.edu.

Quality and Safety
Prior to putting a drug on the market,
manufacturers must establish that the
drug is safe and effective. This requires
extensive, costly and time consuming
testing and clinical trials. The process of
bringing a drug to market takes an
average of 8.5 years and costs, on average,
about $500 million.4
Controversies arise in some cases as to
whether certain substances should be
classified as drugs or regulated by the
FDA. A decision by policy makers that a
substance will not be regulated as a drug
clearly saves the manufacturer a great deal
of time and money, but it may raise
concerns about the safety of the substance
and access to the substance by minors or
uninformed consumers. This has been the
case with both dietary supplements and
tobacco. In 1994, in response to
vociferous lobbying by the vitamin
industry, Congress passed the Dietary
Supplement Health and Education Act,
which classified herbal products as food
supplements rather than drugs. This result
was a compromise “reached after a battle
in Congress between federal health
authorities who wanted tougher safety and
efficacy standards, and herbal companies,
who complained that they could not
afford the sort of clinical testing required
by the FDA for synthetic drugs.”5 In a
recent class in her multidisciplinary course,
Critical Issues in Health Care, Professor Diane
Hoffmann, along with adjunct Professor Frank
Palumbo, had students testify for or against
proposed legislation to regulate dietary
supplements as drugs. According to Hoffmann,
students in the class have strong feelings about the
issue and to what extent these products should be
regulated.
Whether tobacco products should be
regulated as drugs or drug delivery
devices has also been a topic of ongoing
debate. Professor Kathleen Dachille, Director
of the Law School’s Center on Tobacco
Regulation, Litigation and Advocacy, has
argued that from a public health perspective,
there is no question that tobacco products should
be considered a drug. However, political
lobbying by the tobacco industry has prevented
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this from happening for years. Recently,
however, a bill introduced in Congress that
would give FDA authority to regulate tobacco
products gained considerable support from both
sides of the political aisle. Prof. Dachille writes
about the bill in this issue of the newsletter. (See
article, p. 7.)
Once a drug is approved for
marketing, manufacturers are
required to report any adverse
events related to taking the
drug to the FDA. If there are
sufficient reports of serious
adverse events that can be
linked to an approved drug,
FDA can remove the drug
from the market or pressure
manufacturers to do so.
Over the last few months
several drugs for the treatment
of pain have been removed from the
market. Just recently, on April 7th, 2005,
the FDA asked Pfizer to voluntarily
remove Bextra, a Cox-2 inhibitor similar
to Vioxx, from the market because of the
risk of cardiovascular side effects, stroke,
heart attack and serious skin reactions.
Following the recall of Vioxx in
September, 2004, Pfizer began an
aggressive marketing campaign for Bextra,
which was widely prescribed for arthritis
and other acute pain. In December of
last year, the FDA required Bextra to
come with a black box warning, a way to
tell doctors and patients that the drug has
risks and should be prescribed only when
there is no other alternative.
Following a joint meeting of the
FDA’s Arthritis and Drug Safety and Risk
Management Advisory Committees in
February, the FDA concluded that the
overall risk versus benefit profile for
Bextra was unfavorable. The FDA is also
asking manufacturers of all marketed
prescription Non-Steroidal AntiInflammatory Drugs (NSAIDs), including
Celebrex, to revise the labeling for their
products to include a boxed warning,
highlighting the potential for increased
risk of cardiovascular events and the well
described, potentially life-threatening

gastrointestinal bleeding associated with
their use. Manufacturers of over the
counter NSAIDs such as Motrin
(ibuprofen) and Aleve (naproxen) are also
being asked to revise their labeling to
provide more specific information about
the potential cardiovascular and
gastrointestinal risks of their individual
products and remind patients to take
these products in accordance with the
limited dose and duration of
treatment on the package
instructions.
Addiction and Abuse
The reduction in the
number and variety of pain
medications exacerbates an
already existing problem in
our health care system – the
under treatment of pain.
Professor Hoffmann has worked
extensively on this problem,
publishing several articles on legal, financial and
cultural obstacles to pain management. The
problem is in part a result of physician
fear of legal scrutiny and sanction
associated with the prescribing of opioids.
These drugs are classified as controlled
substances under federal law because of
their potential for diversion, abuse and
addiction. The prescribing of opioids is
thus regulated by both the federal Drug
Enforcement Agency (DEA) and the
FDA.
Perhaps the most well-publicized case
of drug diversion in recent years is that of
OxyContin, a medication legitimately
used to treat moderate to severe pain.
OxyContin is a Schedule II controlled
release form of the narcotic oxycodone
manufactured in tablet form. OxyContin
became a “drug of choice” for diverters
and abusers of controlled substances
because of the larger amounts of the
active ingredient in relation to other
previous oxycodone products and the
ability of abusers to easily compromise
the controlled release formulation.
Simply crushing the tablet negates the
timed effect of the drug and enables
users to swallow, inhale or inject the drug
for a morphine-like high. Common
means of OxyContin diversion are

fraudulent prescriptions, doctor shopping,
over-prescribing and pharmacy theft.
The DEA and state drug enforcement
personnel have recently targeted a
number of physicians for arrest and
prosecution who prescribe OxyContin in
large quantities arguing that they are
prescribing the drugs to known abusers.
Professor Hoffmann is currently working on an
article that examines these arrests. She argues
that in several of these cases drug enforcement
personnel and prosecutors are overreaching and
that their actions are having a chilling effect on
the prescribing of opioids for patients with
chronic pain who desperately need these drugs.
(See article, p. 12.)
In cases involving the prescribing of
opioids, prosecutors’ claims are often based
on allegations that the drugs are not being
prescribed for a “legitimate medical
purpose,” as required by the federal
Controlled Substances Act. Questions
regarding whether a drug is being
prescribed for a “legitimate medical
purpose” have also been at the heart of
the debate regarding Oregon’s Death with
Dignity Act (DDA). In 1994, Oregon
enacted the DDA, becoming the only
state to legalize physician-assisted suicide.
Under the DDA, adult Oregon residents
suffering from an incurable disease likely
to result in death are eligible to receive
prescribed medication that would end life.
A physician may prescribe, but not
administer, the medication to the patient.
In all cases, the drugs prescribed are listed
as controlled substances under the
Controlled Substances Act.
In November, 2001, U.S. Attorney
General John Ashcroft issued a statement,
known as the Ashcroft directive, aimed at
Oregon physicians which said that assisting
with suicide is not a legitimate medical
purpose and that any physicians assisting
with suicide under the DDA would be in
violation of the CSA and could face
criminal prosecution and termination of
their ability to prescribe controlled
substances.
In response to the directive, the State
of Oregon, along with an Oregon
physician, pharmacist and several terminally
ill patients, filed a lawsuit against the

Cont. on page 20
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CISTS IN LAW SCHOOL
HARMACISTS

W

hen pharmacist Jeanne Brennan
told her friends and family that
she was going to law school,
they thought she was crazy. Why would
she give up pharmacy, a lucrative career
with a lot of schooling of its own, to go
back to school? And why law school?
Well, it turns out that Jeanne’s path is not
terribly uncommon. She is one of several
current Maryland law students with
pharmacy backgrounds.
Jeanne graduated from the University of
Utah with her pharmacy degree in 1990.
She worked for over ten years as a
pediatric pharmacist at Primary Children’s
Medical Center in Salt Lake City, where
she was a member of a multidisciplinary
ICU team. Although she was doing very
well for herself and her family, Jeanne
started to get bored. Pharmacy is very
technical, she said, and she had reached a
certain level of expertise and thought,
“Now what?” She decided to go to law
school because the law degree would
open up opportunities for her both within
the pharmacy field and without. She
came to the University of Maryland
School of Law as an evening student,
working during the day as a pharmacist at
CVS. During law school, she has worked
contractually for the DC law firm of
Goulston and Storrs on pharmacy related
matters. She is keeping her options open
following graduation this spring. She is
interested in OIG work, lobbying, and
issues related to e-health.
Like Jeanne, Ann Taylor has been a
pharmacist at CVS by day and a law student
by night. She received her PharmD from
the University of Maryland School of
Pharmacy in 1997. She did her postgraduate residency at Washington Hospital
Center and then became a consulting
pharmacist for Mariner Health Medical
Services and Neighborcare Long Term Care
Pharmacies. It was during this experience
working with nursing home patients that
Ann realized the interconnection between
pharmacy and the law. She noticed how
heavily regulated the nursing homes were,
and how scared the nursing home
employees seemed to be of the regulators.

(Left to right) Jeanne Brennan, Ann Taylor, Melanie Torain, Lori Brandes
She says that she came to understand that
“there were laws in place that did not
connect with clinical practice.” In other
words, clinical medicine was moving
forward, and the law was not keeping up.
This is why she decided to go to law
school: “It is important for people in long
term care to be involved with making the
laws that regulate them.”
During law school, Ann had several
experiences in which she felt her
pharmacy background was an asset. She
did a health law practicum at the U.S.
Department of Health and Human Services,
Office of the General Counsel in the
Public Health Division and clerked in the
Maryland Attorney General’s Office in the
Antitrust Division. In both experiences, she
felt her science background and clinical
knowledge proved useful in the tasks she
was asked to complete. She also participated
in the Civil Rights: Access to Health Care
for Vulnerable Populations Clinic in which
she worked for the Coalition to End
Childhood Lead Poisoning. As part of her
clinic experience, she provided legal
assistance to clients involved in claims in
landlord-tenant court who were facing
eviction and had viable legal defenses related
to lead paint. She found that because of her
pharmacy background she was able to
explain to parents, in a way that made sense,
the meaning of the medical terminology

surrounding their child’s lead paint
poisoning. Following graduation this spring,
Ann is considering a career in legislation or
health care compliance.
Melanie Torain is another fourth year
evening student with a pharmacy
background. She was a pharmacy
technician at Rite Aid and then at Johns
Hopkins Hospital for close to ten years.
She then became a radiologic technologist
at Hopkins. During her time at Hopkins
she attended the University of Baltimore
and received her B.S. in Health Systems
Management. As part of her degree
requirements, Melanie took a class in
health law. She was fascinated and knew
then that she would go to law school.
On her way to the health law certificate,
Melanie has taken many health care classes.
Classes such as Health Care Law: The
Provider-Patient Relationship were not so
abstract because she sees those
relationships at work everyday. Because
she also witnesses disparities in health care
on a regular basis, Melanie chose to
participate in the Civil Rights: Access to
Health Care for Vulnerable Populations
clinic. Like Ann, she represented indigent
clients in the Baltimore City District Court
on issues related to lead paint. She is
considering a career in medical malpractice
litigation following graduation.

Cont. on page 6
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Lori Brandes, a second year evening
student, had always liked science, so she
got her bachelors degree in biochemistry
and molecular biology and then went to
graduate school. She received her Ph.D.
in Pharmacology in 2002 from the George
Washington University. She knew that
she wanted an alternative career in science,
but it wasn’t until she had lunch with a
friend one day that she considered law.
Her friend from graduate school was
working for a patent law firm and told her
that many patent law firms had a need for
people with scientific expertise. Lori
looked into it and applied for a Technical
Specialist position with Sterne Kessler
Goldstein Fox in D.C. Sterne Kessler has
a program in which they train people with
technical backgrounds about the patent
process and then help them to become
patent agents and/or go to law school.
After a year as a technical specialist, Lori
went to law school, at which time she
became a Student Associate with the firm.
In her first two years of law school, Lori
feels her pharmacy background has been
very helpful. She believes the analytical
skills she gained in graduate school have
helped her with issue-spotting and
conveying information in a clear and
concise way. Prior to graduation Lori will
sit for the patent bar. Upon graduation
she hopes to become an associate with
Sterne Kessler.
These four students entered law school
with a unique perspective on life. They
all believe their pharmacy backgrounds
have been advantageous to them in law
school and will help them get their desired
job following graduation. Maybe the
notion of a pharmacist going to law school
isn’t so crazy after all!

O

ver the last few years, the issue of
importation of prescription drugs
from foreign countries has
received considerable attention from
legislators, the media and the public.
Advocates for the practice argue that
importation introduces much needed price
competition into the marketplace and
makes drugs affordable for U.S. seniors.
The Food and Drug Administration
(FDA), however, warns that drug
importation is unsafe
and illegal because
the drugs may not
meet U.S. standards.
In defiance of the
FDA, at least 14 states
and numerous local
governments have
announced plans to,
or have taken steps
to, import lower cost
prescription drugs
from Canada. In an
effort to explore the complexities of this
issue, the Law & Health Care Program in
conjunction with the School of
Pharmacy’s Center on Drugs and Public
Policy hosted a Forum on Drug
Importation on October 27, 2004.
The panel included law professor Tom
Perez, who is also President of the
Montgomery County Council and
represents 180,000 residents of
Montgomery County; William Hubbard,
Senior Associate Commissioner for Policy,
Planning and Evaluation for the FDA and
the FDA’s point person on drug
importation; Cynthia Boyle, Assistant
Professor at the School of Pharmacy,
current president of the Maryland
Pharmacists Association and an officer in
the American Pharmacists Association; and
Dr. Peter Rost, Vice President of Pfizer
Pharmaceuticals, who has had 20 years of
experience marketing pharmaceuticals and
has been involved in drug importation in
Europe for Pfizer. The panel was
moderated by David Knapp, Dean of the
School of Pharmacy and a founder of the
School’s Center on Drugs and Public
Policy.

Dean Knapp set the stage for the
discussion by highlighting a few statistics.
He noted that the cost of prescription
drugs is rising, and the number of
prescriptions written in the U.S. has
doubled in the last couple of years to 3.3
billion prescriptions dispensed in 2003.
Total prescription drug sales in the U.S. in
2003 were $228 billion, while the dollar
amount of prescriptions imported from
Canada in that year was $1.1 billion.
Professor Perez
kicked off the panel
by discussing the fiscal
crisis that Montgomery
County is currently
facing. Like every
county in America, he
said, Montgomery
County has unfunded
mandates from the
federal and state
governments and has
had to cut vital
community services such as ladder trucks
and school programs because of the
budget crisis. As a Council member, he
looked at the County’s balance sheet to
see what factor was “killing” the budget.
It turned out to be the cost of
prescription drugs to county employees
and retirees, which had doubled in six
years. In an effort to save money in this
area, the County Council began to explore
the option of importing drugs from
Canada for its employees. With the help
of a technical advisory group, the Council
concluded that the Canadian system was
safe and cost effective. Although the legal
issues are muddled, the Council is going
forward with a prescription drug mail
order program for its retirees. Requests
for proposals went out in February. The
Council is in the process of reviewing a
number of bids and will make a decision
some time this spring.
Bill Hubbard outlined the FDA’s long
list of concerns over the importation of
foreign drugs. In particular, the FDA is
concerned with untruthful websites,
questionable sources of drugs, counterfeit

Cont. on p. 7
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drugs, controlled substances coming into
the country illegally, and the Canadian
market running dry. He also pointed out
that, in many cases, you can beat the
Canadian price for a drug by buying its
generic equivalent here in the U.S. In the
end, he said, cost-saving should not come
at the risk of safety.
Professor Cynthia Boyle opposes the
importation of drugs from Canada.
Whenever money is involved, she said,
there is a risk to safety. She fears that
importation is an end run around U.S.
safety regulations and believes that drug
importation is an example of treating the
symptom of a problem instead of the
underlying cause. If we focus on
prevention of health problems, she said,
the overall cost of health care in this
country will go down. She proposes
providing incentives for pharmacists to
look over patients’ drug regimens to
reduce the number of their prescriptions,
providing incentives for doctors to keep
patients well, and encouraging people to
take better care of themselves.
The last speaker was Dr. Peter Rost.
To counter the FDA’s argument that drug
importation is unsafe, Rost points to
Europe, where reimportation has been
carried out safely for 20 years. He said that
we hear all about how unsafe importation
is, but “we haven’t seen a dead body yet.”
Moreover, while the FDA is attacking
reimportation, the real safety concern
should be that we have people in this
country choosing between their
prescription drugs and food. He believes
that “importation is no substitute for
meaningful health care reform, but in the
meantime, we must play the hand we’re
dealt.” If the government would regulate
importation, it could ensure safety and
help the uninsured by providing an
alternative supply channel for prescription
drugs.

P

ublic health advocates have
campaigned for federal legislation
granting the Food and Drug
Administration authority to regulate tobacco
products since the Supreme Court ruled in
2000 that the agency lacked such authority in
FDA v. Brown & Williamson Tobacco Corp.,
529 U.S. 120 (2000). A close call on
legislative efforts in 2004 inspired advocates

that the agency would evaluate whether
an action regarding a tobacco product
would protect the public health. In
addition, the bill would grant the FDA
authority to:

•Restrict tobacco advertising;
•Require disclosure of all
ingredients and additives in tobacco
products;

•Alter health warnings on cigarettes
and smokeless tobacco and in
advertisements;

•Prohibit tobacco companies from
marketing “modified risk” products
unless the FDA approves of the
product and the marketing plan.
to return to Congress this year with a clear,
comprehensive and bipartisan bill giving FDA
that authority. The DeWine-Kennedy bill
(S. 666) and the Davis-Waxman bill (H.R.
1376) were introduced March 17, 2005 with
the support of the Campaign for TobaccoFree Kids, American Cancer Society,
American Heart Association, and American
Lung Association.
During the 2004 Congressional session, the
FDA regulation bill was merged in the
Senate with an important corporate tax bill
and in the House with a bill that would
provide $10 billion as a “buyout” to tobacco
growers. Both the tax bill and the buyout bill
were destined for passage and tobacco
control and public health advocates were
optimistic that, as an add-on to these bills,
FDA regulation of tobacco would pass as
well. Despite Herculean efforts by advocates
and key legislators, the tax and buyout bills
passed without the FDA provisions. In
response, a free-standing bill providing FDA
regulation of tobacco was introduced. That
bill passed the Senate (78-15) but died in the
House without a vote.
Like the 2004 version, the 2005 version of
the FDA bill creates a new standard by
which the federal agency is to evaluate
tobacco products. Currently the FDA may
approve of a drug or device if there is a
reasonable assurance that a product is “safe
and effective.” As there is no safe and
effective tobacco product, the bill provides

Although the bill allows the FDA to
require product modifications, such as
reduction of nicotine, Congress retains
exclusive power to require the
elimination of nicotine or to ban the
sale of cigarettes, cigars or smokeless
tobacco. In contrast to an existing
federal law with a broad preemption
clause, the bill grants state and local
governments some authority over
tobacco marketing.
FDA regulation of tobacco is
considered an essential element in a
comprehensive public health plan to
reduce tobacco-related illness and death.
Effective federal regulation should result
in diminished youth access to tobacco,
decreases in adult smoking prevalence
and a better-educated consumer. Such
regulation would complement and
extend the effectiveness of smoke-free
workplace laws, youth sales enforcement
programs, cessation services, and other
regulatory, economic and social strategies
to improve public health by reducing
tobacco use. For more information about
the 2005 bills or to track the legislation,
visit www.tobaccofreekids.org/reports/
fda.
Professor Kathleen Dachille
Director, Center for Tobacco
Regulation, Litigation & Advocacy
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COMPULSOR
Y LICENSING PANEL
OMPULSORY

I

n recent years, many policy experts
have advocated for alternative drug
access policies given the continued
threat of bioterrorism and the rampant
HIV/AIDS crisis around the world. On
March 7, 2005, the Maryland Intellectual
Property Student Association (MIPSA) and
the Student Health Law Organization
(SHLO) co-sponsored a forum on
“Compulsory Licensing and Access to
Medicines” to examine whether
compulsory licensing of pharmaceuticals
could increase access to life-saving drugs
during times of national emergencies and
for HIV/AIDS patients and patients
suffering from other diseases. Compulsory
licensing is the legal mechanism which
allows the government to compel a
patented-drug-maker to license the right
to produce and market its patented drug
to a generic drug manufacturer in

exchange for a royalty. The generic drug
manufacturer can often produce the drug
at a much cheaper price than the
patented-drug making company, and the
drug is financially accessible to a broader
range of people than it would otherwise
be. The panelists weighed the costs and
benefits of compulsory licensing.
The forum featured Robert A.
Freeman, Ph.D. (Senior Scholar,
Department of Health Policy, Thomas
Jefferson School of Medicine), Michelle S.
Marks, Ph.D., J.D. (Special Counsel, Shaw
Pittman, LLP; UM ‘96) and Peter J. Weina,
M.D., Ph.D. (Chief of Pharmacology,
Walter Reed Army Institute of Research).
The panel session was moderated by
Professor Francis B. Palumbo, Ph.D., J.D.
(Director, Center on Drugs and Public
Policy, University of Maryland School of
Pharmacy). The audience engaged the

panelists in a lively discussion about the
need to increase access to life-saving
medicines and the prospects of
compulsory licensing in achieving such a
goal. Dr. Marks and Dr. Freeman
suggested that compulsory licensing would
infringe on intellectual property rights and
could stifle discoveries of innovative, lifesaving drugs. Dr. Weina, an expert on
tropical medicine and infectious diseases,
concluded that compulsory licensing or
other suggested policy alternatives cannot
realize their desired outcomes until proper
distribution infrastructures are established
in crisis-stricken areas.
Rachael Melby (SHLO)
Ravi Upadhyay (MIPSA)
University of Maryland
School of Law, ‘05

FOOD AND DRUG LAW CAREER PANEL

O

n February 9, 2005, the Student
Health Law Organization (SHLO)
highlighted the variety of career
opportunities existing in the area of food
and drug law by hosting a panel of
speakers who practice in this highly
specialized field. The panel consisted of
three University of Maryland School of
Law alumni who work on issues related to
food and drug law but in different
practice settings. The panel members
answered questions from students and
gave them some personal insights about
their work in the field and their career
paths. They also provided some advice for
any in the audience who might be aspiring
food and drug law attorneys.
Deborah Shelton, a 7th year associate at
Arent Fox in Washington D.C., discussed
the practice of food and drug law from
the vantage point of an attorney in a
private firm. Although she did not have a
scientific background and had not initially
planned to practice food and drug law,
she found her love for the field as a
summer associate at the firm and joined
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the practice group after graduation. Her
work has included everything from
labeling issues to patent rights. One of the
topics about which she spoke at length
was the cost and availability of
biopharmaceuticals. (See her article, p. 9.)
Jayson Slotnik, the Director for
Medicare Reimbursement and Economic
Policy at the Biotechnology Industry
Organization (BIO), spoke about his
experiences as a policy analyst and attorney
for a trade association. Always interested
in health care issues, Mr. Slotnik received
his MPH and was an epidemiologist for
several years prior to attending law school.
He initially joined a major health law firm
in Washington, D.C. after law school, but
he was hoping to find a job which would
better enable him to combine his public
health and legal backgrounds. Describing
his current position as the “perfect” job
for him, Mr. Slotnik told students about
the fast paced and unpredictable life of a
policy analyst in food and drug law.
Second year law student Linda Souter is
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externing with him at BIO this semester.
(See her account of her experience, p. 15.)
Dr. Peter Rheinstein, publisher of the
journal Discovery Medicine and former
Director of FDA’s Office of Drug
Standards, told students about the
government side of food and drug law. He
gave a unique “insiders” perspective on
how the FDA works and deals with legal
issues. Dr. Rheinstein enrolled in law
school in the evening program while he
was a full-time practicing physician. He
found the FDA to be an ideal place to
work given his medical and legal
backgrounds. Having spent over 20 years at
the FDA, Dr. Rheinstein spoke to students
about the cutting-edge and substantive
work with which he was involved and
being at the forefront of setting regulatory
standards. He currently provides consulting
services for pharmaceutical companies on
regulatory matters.
Mona Shah
University of Maryland
School of Law, ‘06

WILL BIOPHARMA
CEUTIC
ALS SOON
IOPHARMACEUTIC
CEUTICALS
FACE COMPETITION FR
OM GENERICS?
FROM

M

ore than $10 billion worth of
branded biologicals are
anticipated to go off patent in
the U.S. within the next two to three
years. Unlike chemically synthesized
drug products, none of these products
currently face the prospect of competition
from generics. Yet, many of these
biopharmaceuticals can, for a single patient,
cost upwards of $1,000 per month, and in
some cases, tens of thousands of dollars a
year. Unlike conventional chemically
synthesized pharmaceuticals, however, there
is, at present, no abbreviated approval
pathway for would-be generic versions of
biopharmaceuticals. That absence has
begun to garner increasing attention,
spurred on by the convergence of two
critical factors: the increasing promise of
biopharmaceuticals as breakthrough
medical therapies and the need to render
those therapies accessible to patients
without financially overburdening the
U.S. healthcare system.
Thus far, Congress has played only a
very small role in the debate. It has
instead decided to allow the U.S. Food
and Drug Administration (FDA) to take
the lead. To date, FDA has maintained
its primary focus on the scientific issues
that it has identified as being central to a
determination as to whether an
abbreviated approval pathway should be
created for a generic version of a brand
name biopharmaceutical.
Legal Overview. With few exceptions,
including human growth hormone and
insulin, biologics are approved under the
Public Health Service Act (PHSA).
Drugs, by contrast, are approved under
the federal Food, Drug and Cosmetic Act
(FDCA). Full new drug applications
(NDAs) under the FDCA, and biologics
license applications (BLAs) under the
PHSA, require complete reports of preclinical and clinical data to support
approval. A crucial difference arises,
however, in the context of biologics
approved under the PHSA. Unlike the
FDCA, the PHSA includes no abbreviated
approval pathway for a generic version of a
previously approved biologic. Therefore,
the consensus is that the creation of an
abbreviated approval pathway for a

generic biopharmaceutical will require
legislation. Indeed, FDA itself has
acknowledged the need for statutory
authority in order to do so. Moving
toward legislative and regulatory change
requires resolution of a set of difficult
scientific and technical questions.
Scientific Issues Raised by the Prospect of
Generic Biologics. The scientific arguments
surrounding the debate can be
classified as deriving from two main
premises: (1) that unlike chemically
synthesized drugs, biologically derived
products raise special concerns due to their
molecular size, complexity, and heterogeneity;
and (2) that there is an inextricable link
between a biologic’s manufacturing process
and its clinical attributes.
On the first point, some argue that the
chemical composition and structure of a
chemically synthesized drug can be
determined precisely by physical and
chemical assays, and thus any differences
between a reference listed drug and a
proposed generic version can be readily
identified. In contrast, the complexities of
many biologics make it difficult, if not
impossible, to fully characterize, and thus
any differences between a biological and a
proposed generic version, and the potential
clinical effect of any such differences, are
difficult, if not impossible, to identify and
assess.
On the second point – often framed
as the “product is the process, and the
process is the product” – some argue that
unlike the clear and linear manufacturing
process of a chemically synthesized drug,
biopharmaceuticals have an inherent
metabolic and synthetic variability that
renders them vulnerable to minute
differences between manufacturing
processes, which, in turn, may cause
significant differences in the clinical
properties of the products. Thus, the
argument continues, it is simply not
possible for different manufacturers to
produce an identical biological product;
therefore, FDA should require a full
complement of pre-clinical and clinical
data as part of each and every marketing
application for a biological product.
Next Steps. On August16, 2004, FDA
issued a Federal Register Notice summarizing

the specific scientific issues it identifies as
critical to the biopharmaceuticals debate.
These scientific issues have been the subject
of two public hearings within the past
calendar year and a public docket of
submission of written comments. FDA has
announced that it will set forth its findings
and conclusions on these and other relevant
scientific issues in a draft guidance
document. The primary focus of this
guidance is anticipated to be on defining
how the Agency evaluates issues related to
biological comparability across different
regulatory schemes and in different stages of
product lifecycles. FDA has described the
intended purpose of this guidance as to
ensure that a consistent scientific approach is
applied across biological products, regardless
of whether they are approved under the
FDCA or PHSA. This guidance will likely
issue in the form of a series of draft guidance
documents, each one discussing one or
more of the scientific issues raised in the
biopharmaceuticals debate.
Before it issues any of the so-called
“scientific framework” guidance
documents described above, however,
the Agency has announced that it will
first issue a background document that
provides a comprehensive historical
overview of the regulatory and scientific
steps that the Agency has taken with
regard to biological products over the
past 50 years. Once these documents are
issued, FDA may hold one or more
public hearings to receive additional
input on them. Finally, based on the
current state of affairs, it is probable that
only after FDA has issued more definitive
findings on the scientific questions that
the arduous legislative process will begin.
In sum, it is likely that some sort of
abbreviated approval pathway for generic
biopharmaceuticals will be created at some
point in the future. Given the numerous
and complex scientific issues that remain
to be resolved, however, and the need for
legislation to create such a pathway for
most biologics, it is likely to be at least
another two to three years before such a
process is actually put into place.
Deborah M. Shelton, ‘98
Arent Fox PLLC
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ROME LECTURE EXPLORES
MEDIC
AID IN ITS FOR
TIETH YEAR
EDICAID
ORTIETH

O

n March 10, 2005, the Law &
Health Care Program sponsored
the annual Stuart Rome
Lecture. This year’s distinguished speaker
was Sara Rosenbaum, the Harold and Jane
Hirsh Professor of Health Law and Policy
and Chair of the Department of Health
Policy at the George Washington
University Medical Center, School of
Public Health and Health Services.
Professor Rosenbaum’s lecture was
entitled “The Elimination of Racial and
Ethnic Disparities in Health Care:
Focusing on What Is Real and True in
Medicaid’s Fortieth Year.”
The Rome Lecture was established by
Stuart Rome’s family and friends to
celebrate Rome’s life and work. In her
introduction, Dean Karen Rothenberg
cited Rome as a pioneer in the field of
health law, particularly with regard to
issues crossing racial and religious lines.
Rosenbaum has similarly made many
significant contributions to health law and
policy. Rosenbaum has focused her career,
beginning as a legal services attorney for the
poor, on improving access to health care
for low income, minority and medically
underserved populations. She has played a
major role in the design of federal and state
legislative and regulatory health policy in a
wide range of areas, including Medicaid,
private health insurance and employee
health benefits, health services for medically
underserved persons, maternal and child
health, civil rights, and public health. In
1993 and 1994, Rosenbaum worked for
the White House Domestic Policy
Council, where she directed the drafting of
the Health Security Act for President
Clinton. Rosenbaum has been named one
of America’s 500 most influential health
policymakers and has been recognized by
the U.S. Dept. of Health and Human
Services for distinguished national service
on behalf of Medicaid beneficiaries.
Rosenbaum’s lecture focused on the
realities of ethnic and racial health
disparities and the challenges of financing
adequate health care for minority
populations through Medicaid. The
Medicaid program supports health care for
the nation’s poorest and most vulnerable
10

residents, and is the health care safety net
on which they depend. Rosenbaum
stressed that Medicaid’s role in our health
care system cannot be underestimated
because it is the single largest health
insurance program and the most important
program for minority populations
nationwide. There are significant
correlations between proportions of
minorities and the presence of uninsured
populations in most states, and many health
care problems and health care needs are
statistically greater in minority populations.
Rosenbaum believes that the country is
poised for a huge public conversation
about Medicaid. According to
Rosenbaum, the program is a victim of its
own successes, and much of health care
reform over the last forty years has in
some way been tied to Medicaid. The
program has helped to shape health policy
and the nation’s response to significant
public health crises, including infant
mortality, the tuberculosis epidemic of
the 1980s, HIV, aging of the population,
child developmental disabilities and the
incidence of breast and cervical cancer
among low income women. However,
this significant and yet most
misunderstood of all public programs
faces unprecedented challenges to its
survival. Rosenbaum described the
challenge of fixing Medicaid as a “passion
play” that has unfolded as Congressional
budget committees call for major
spending reductions in Medicaid.
Constraints in state spending make the
suggestion of such reductions even more
significant. Currently, much of the
power to effect change is held by
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proponents of the federal government’s
desire to switch Medicaid to a defined
contribution program.
The debate over Medicaid is highly
political. Rosenbaum believes that the
fate of Medicaid may depend on how
Americans and policymakers who
represent them, respond to the ongoing
debate. She described the Medicaid
debate as “double edged” and spoke
about the importance of illustrating to
state policymakers that there is pain felt
on both sides of the issue. Proponents
of Medicaid argue that there is nothing
“optional” with respect to the program’s
services and the populations that
Medicaid covers, presenting strong
arguments for finding ways to fix the
program because it is a vital part of our
health care system. Alternately, other
policymakers believe that making certain
cuts in Medicaid funding is required as a
first step to making cuts in other parts of
the health care system. There is no
consensus among states about the best
way to reform Medicaid. Although a
purely federal program would eliminate
pressure from individual states, it would
require decisionmakers in the federal
government to make decisions while
being farther removed from the
populations that Medicaid most affects.
Medicaid is, as Rosenbaum
concluded, easy to misunderstand and
even easier to entirely overlook in larger
national debates about the fate of our
country’s health care system. However,
changes affecting the fate of Medicaid
represent a potentially profound shift in
U.S. health care policy that may
fundamentally alter relationships between
Americans, especially minority Americans,
and our health care system. How these
challenges are resolved not only will
shape the health care system for decades
to come, but also will test the
commitment of political leaders to the
reduction of racial, ethnic, and economic
disparities in health care.
Amy F. Siegel
University of Maryland School of Law, ‘07
Adapted from an article in The Raven,
Vol. XVII No. 4 (April 14, 2005)

CONFERENCE ON RACIAL AND ETHNIC
DISP
ARITIES IN HEAL
TH CARE
ISPARITIES
EALTH

O

n March 11, 2005, the Law &
Health Care Program in
conjunction with the Journal of
Health Care Law & Policy and the Abell
Foundation hosted a conference entitled
“Bridging the Racial Divide in Health
Care: Eliminating Racial and Ethnic
Disparities in Health Status.” Conference
organizer Professor Tom Perez, gathered an
impressive line-up of speakers to discuss
promising practices for eliminating health
disparities, the role of the legislative branch
in combating disparities, increasing
workforce diversity as a strategy to eliminate
disparities, and foundations and government
funders as catalysts to eliminate disparities.
Among the keynote speakers was the
Deputy Director of the National Institutes
of Health, Raynard Kington, M.D., Ph.D.

Prof. Tom Perez and Dr. Raynard Kington
Dr. Kington was appointed to this position
on February 9, 2003. In this capacity, he
shares in the overall leadership, policy
direction, and coordination of NIH
biomedical research and the research
training programs of NIH’s 27 Institutes and
Centers. Prior to this appointment, Dr.
Kington was Associate Director of NIH for

Behavioral and Social Sciences Research.
Dr. Kington’s own research has focused on
the role of social factors, especially
socioeconomic status, as determinants of
health. His current research includes studies
of the health and socioeconomic status of
black immigrants, differences in populations
in willingness to participate in genetic
research, and racial and ethnic differences in
infectious disease rates. In his conference
address, Dr. Kington stated that every
person and every organization has a role to
play in the movement to eliminate
disparities in health care. Researchers,
government, health care providers and
community organizations alike must all
make strides to address this challenge. Dr.
Kington ended his talk with the following
narrative: “Many years ago, I remember
being told that dealing with large social
problems like health disparities is like
dancing with a bear: you can’t sit down
when you get tired. You have to wait for
the bear to get tired. As you will hear over
and over again at this conference no doubt,
it is high time for each of us to put on his
dancing shoes and get to work.”
Congressman Elijah Cummings also
spoke at the conference. Congressman
Cummings, a graduate of the University
of Maryland School of Law, has been a
member of the U.S. House of
Representatives since 1996 and is now in
his sixth term in Congress. He serves on
the House Government Reform
Committee, is the Ranking Member of
the Criminal Justice, Drug Policy and
Human Resources Subcommittee and is a
member of the Wellness and Human
Rights Subcommittee. In addition to his

Congressman Elijah Cummings
standing committee assignments,
Cummings is the co-chair of the House
AIDS Working Group and is a member
of the House Task Force on Health Care
Reform. He is the immediate past chair
of the Congressional Black Caucus. At
the conference, Congressman Cummings
related the story of his grandfather, who
died before his time, in part due to racial
prejudice by his physician. Because of
this personal tragedy, Congressman
Cummings has been determined to seek
solutions to the health disparities
problem. In his remarks, he said, “I
believe that health care is a fundamental
right of every human being. I ask you
who share this vision to work with us.
Our goal is a health care system that truly
serves ALL Americans. Now is the time
to transform our human right to health
care into a civil right guaranteed by
federal law.”

L&HCP Ranked in Top Three in
U.S. News & World Report Survey
The Law & Health Care Program ranked third in U.S. News & World Report's 2004
annual survey of law school specialty programs. Since 1995, the L&HCP has been
consistently named among the top five health law programs nationwide.
www.law.umaryland.edu/specialty/maryhealth/index.asp –– Law & Health Care Newsletter 11

SPO
TLIGHT ON ...
POTLIGHT
F ACUL
TY SCHOLARSHIP
CULTY
Diane Hoffmann

P

rofessor Hoffmann and colleague,
Anita Tarzian, Ph.D., recently
completed an article entitled
“Dying in American Nursing Homes:
An Examination of Policies that Deter
Adequate End-of-Life Care.” In the
article, which is forthcoming in the
Journal of Law, Medicine & Ethics,
Hoffmann and Tarzian assert that dying
nursing home residents often do not
receive appropriate end-of-life care and

could benefit substantially from
enrollment in hospice. Studies have
shown that nursing home patients enrolled
in hospice, when compared to those at
the end-of-life who were not in hospice,
are less likely to be hospitalized in their last
six months of life, receive superior pain
assessment and treatment, and are less
likely to be physically restrained or have
feeding tubes. While utilization of hospice
care has increased during the last decade,
there is considerable evidence that hospice
care remains underutilized in the long term
care setting. There are a host of reasons for
this lack of utilization, but Hoffmann and
Tarzian focus on several government
policies including Medicare regulations
that define hospice eligibility and the type
of care that must be provided to nursing
home residents, reimbursement of both
hospice and nursing home care, and
initiatives of the Office of the Inspecor
Gemeral to combat fraud in this area.
They argue that these policies and
practices are based on questionable
12

assumptions about “where people die, the
predictability of death, and the financial
incentives of nursing homes to utilize
hospice.” As a result, they call for a shift in a
number of paradigms that have affected
policies related to caring for nursing home
patients at the end-of-life.
Hoffmann is currently working on an
article tentatively titled: “Arrest and
Prosecution of Physicians for Prescribing
Opioid Analgesics: The Indirect Costs of
Prosecutorial Overreaching.” In the piece,
Hoffmann questions the actions of some
federal and state prosecutors who have
arrested and charged scores of physicians
with criminal violations related to their
prescribing of opioid analgesics. In a
number of these cases, the charges were
subsequently dropped, or if the provider
was found guilty at the trial court level, the
verdict was overturned on appeal. The
motivation for this increased legal action on
the part of prosecutors appears to have its
roots in the war on drugs and the recent
spate of deaths related to the abuse of
OxyContin. While the intense scrutiny is a
response to a relatively new drug,
prosecution of physicians related to the
prescribing of narcotics has a long history in
this country, and drug regulators have long
attempted to balance negative effects
(toxicity, addiction, and diversion) with
positive effects (therapeutic benefit and
pain relief). In the article, Hoffmann argues
that these recent actions by prosecutors
have led to a significant imbalance in the
administration of drug control policy and
that in a number of cases law enforcement
officials are wrongly construing the
definition of “legitimate medical purpose”
and are overstepping the boundaries of
appropriate prosecution. As a result, she
argues, they are harming not only the lives
of the physicians wrongly accused but also
the patients of these physicians and other
individuals who suffer from chronic pain.
The law enforcement climate surrounding
prescribing of opioid analgesics appears to
be causing some physicians to stop
prescribing opioids or to stop treating
chronic pain patients, reducing to a very
small figure the number of physicians who
are willing to treat these needy patients.
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Robin Wilson

P

rofessor Robin Wilson continues
her work on nanotechnology. (See
article, p. 9, L&HCP Newsletter, Fall
2004.) Recently, she presented a paper
entitled “Planning for the Unknown:
Lessons from Bioterrorism” at a national
conference on Nano Ethics at the

University of South Carolina, where she
proposed a unique framework for
regulating the new technology.
Some have argued that we should
anticipate nanotechnology’s possible
darker side by regulating individual
applications or all nanotechnologies.
Wilson highlights the difficulty of
regulating a newly emerging technology in
advance of actual experience and argues
instead that we should regulate the entities
that are developing nanotechnologies.
Specifically we should plan for the
possibility of a bad outcome by requiring
companies to insure against such risks.
In advocating for this approach,
Professor Wilson cites the fact that the
United States has not adopted a
precautionary principle as a basis for risk
regulation. In fact, the U.S. Supreme
Court has held that agencies cannot
regulate on the basis of mere speculation
about uncertain risks, but must act
instead on a demonstrably significant risk.
Any regulation of the technology, rather
than the entity, also raises significant
definitional problems about scope and

the difficulty classifying exactly what
activities fall into nanotechnology. All of
chemistry concerns atoms and molecules
already on the nanoscale, the regulation of
which would be unfeasible and
undesirable. Equally challenging, the
government has historically regulated a
field only after a devastating event has
already occurred. The Clean Water Act
resulted form the polluting of the
Cuyahoga river, Congress enacted CERLA
in the wake of toxic waste dump sites like
the Love Canal, and September 11th gave
rise to the Patriot Act, the Homeland
Security Act, and Terrorism Insurance
Act. Regulation after adverse events
offers a number of advantages because the
event highlights the need for regulation,
crystallizes the policy choices we face, and
allows us to consider real, not perceived,
costs of regulating or choosing not to
regulate, making the regulations we adopt
more meaningful. This is the same reason
why courts in the U.S. are loath to give
advisory opinions, choosing instead to
consider only live cases and controversies.
Additional problems with anticipatory
regulation are that it could result in too
much regulation, unnecessarily stifling
technological development, or too little
regulation resulting in unchecked
practices. Wilson’s article will appear in a
forthcoming symposium issue addressing
the topic of regulating nanotechnology,
to be published by the Journal of Law,
Medicine & Ethics. She will serve as a coeditor for the issue.

Dan Gilman

V

isiting Professor Daniel Gilman,
J.D., Ph.D., is working on several
articles touching on issues related
to the regulation of drugs. His article
“‘Thou Shalt Not Kill’ as Defeasible
Heuristic: Law and Economics and the
Debate over Physician-Assisted Suicide” is
slated for publication this spring in the
Oregon Law Review. There, Gilman takes a
critical look at Judge Richard Posner’s
account of physician-assisted suicide
(PAS), one of the very few economically
framed analyses of the topic. In his book,

Aging and Old Age, Posner offers a sort of
cost benefit analysis favoring the
legalization of PAS. Central to Judge
Posner’s account is a view of PAS as a
technological innovation that brings a
radical reduction in critical information
costs attending end-of-life decisionmaking. Professor Gilman argues that
Judge Posner’s model—although
innovative and instructive—is incomplete
and, consequently, inadequate to the

normative task of justifying a change in
legal regime. Of central concern, is the
failure to address the larger social costs of
errors—legally sanctioned (and perhaps
publicly funded) non-voluntary killings.
Examining the relevant behavioral
literature, Gilman argues that such errors
are liable to be frequent under Posner’s
scheme or any plausible alternative.
Gilman asserts that the task of assessing
the costs of PAS is probably intractable,
and that the legal prohibition of PAS in
nearly all the states should be “regarded
as a strong default position.”
As a follow-up to that article,
Professor Gilman is working on a paper
entitled “Poison Pills: Oregon v. Ashcroft
and the Regulation of Dangerous
Substances.” Attempts to establish a
constitutional right to PAS on due
process and equal protection grounds
were repudiated by the Supreme Court
in the last decade, thus casting the debate
about PAS back into the states.
Recently, however, then-U.S. Attorney
General John Ashcroft advocated that
Oregon physicians practicing PAS

pursuant to Oregon’s “Death with
Dignity Act” are in violation of the
federal Controlled Substances Act. In
May 2004, a divided panel of the U. S.
Court of Appeals for the Ninth Circuit
rejected the Attorney General’s position
as unenforceable. Professor Gilman
argues that the Attorney General’s
enforcement position appears eminently
defensible, given the established statutory
scheme and well-established principles of
agency deference. He suggests that the
Ninth Circuit’s decision is variously
problematic, although quite possibly
limited in its reach. He also suggests that
the case raises interesting questions
regarding the fit between extant
regulatory categories and the regulation
of certain dangerous substances (e.g.,
recent legislative attempts to establish
FDA regulatory authority over tobacco
products as a species of over-the-counter
drugs.) The Supreme Court has just
announced that it will hear the case (now
captioned Gonzalez v. Oregon) next term,
and Professor Gilman will incorporate the
Court’s opinion in his discussion.
Professor Gilman is also working on an
article addressing “Price Discrimination
and Property in the Pharmaceuticals
Industry.” Price discrimination between
U.S. and Canadian Pharmaceuticals
markets is a conspicuous and contentious
area of policy debate. Little examined,
however, is the question of how general
economic models of price discrimination,
as species of monopolist price setting,
may illuminate the debate about drug
prices and the hotly contested “solution”
of drug reimportation. Gilman argues
price discrimination within and across
U.S. borders is such that the cost to U.S.
consumers of international price
discrimination may not be as large as
many have thought. Furthermore, he
asserts that extant drug reimportation
schemes are not likely to provide
substantial long-term price relief to U.S.
consumers of drug products. He does,
nonetheless, suggest the need to
reexamine the variety of statutory and
regulatory property protections in the
U.S. that form the basis of price
discrimination in the pharmaceuticals
market.
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Judge John Fader

M

any people know that Judge
John Fader is a retired
Baltimore County Circuit
Court Judge and a senior judicial fellow
who teaches several courses at the School
of Law. What many people do not
know is that Judge Fader is also a
licensed pharmacist.

Judge Fader graduated from the
University of Maryland School of
Pharmacy in 1963. During the last year of
pharmacy school, he took a class called
Pharmacy and the Law. This class and
the professor who taught it greatly
influenced Fader, and he and three other
students from his graduating class decided
to go to law school. Fader practiced
pharmacy while attending the School of
Law at night. He graduated from the
evening program in 1968 and was sworn
into the Maryland Bar on November 26,
1968.
During law school, Fader assumed that
after he graduated he would go to work
for a pharmaceutical company or
pharmaceutical association. In the first
semester of his last year of law school,
however, Fader took a law clerk position
for a local attorney. It was through this
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experience that Fader grew to realize he
wanted to be a litigator. Following
graduation from law school, he started his
own practice in Towson, MD. From
1970 to 1977, Fader worked in private
practice. Among other things, he was
general counsel to St. Joseph’s Hospital
and represented five or six contractors.
After seven years of private practice,
Fader had become what he calls “a
glorified business consultant.” He spent
most of his time writing contracts and
sitting in on business meetings. What
truly interested him was “the law,
litigation, analyzing cases,” so in 1977 he
ran for a judicial position. On November
23, 1977, he became a judge for the
District Court of Baltimore County. He
later ran for election to the Circuit Court
for Baltimore County and was sworn in
on February 10, 1982 for a fifteen year
term. He ran again in 1998. He served
five years of his fifteen year term and
retired from the bench in 2003.
Fader continues to be active in
teaching, both here at the law school and
in the pharmacy school. He has taught
Pharmacy and the Law at the pharmacy
school every year since 1974. He has
been an adjunct at the law school for
seven years and teaches classes such as
Family Law, Maryland County and State
Administrative Law, Administrative Law,
and Maryland Civil Procedure.
Fader maintains his pharmacy license
and says that his pharmacy degree made
him a better lawyer and judge: “The
method of science and drugs has made
me very meticulous and detail-oriented.”
Pharmacy was also what allowed him to
make a living to get through law school.
“I keep my pharmacy license up. I’m
very proud of being a pharmacist, and
one who graduated from Maryland’s
pharmacy school.”
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D

r. Frank Palumbo is both a
licensed pharmacist and a
member of the Maryland Bar and
has practiced both pharmacy and law.
He teaches Pharmacy Law at the School
of Pharmacy and has been teaching Food
and Drug Law at the School of Law since
1997.
Dr. Palumbo received his B.S. in
pharmacy from the Medical University of
South Carolina in 1968. He was then
drafted into the army and assigned to the
Pentagon until 1971. From 1971 to 1974
he worked on his M.S. and Ph.D. in
Health Care Administration at the
University of Mississippi. He then joined
the faculty at the University of Maryland
School of Pharmacy. Over the course of

several years, Dr. Palumbo took law
classes at the University of Baltimore
because he was “always interested in legal
issues as they pertained to drugs and
pharmacy.” In 1982, he completed his
J.D.
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During 25 years at the School of
Pharmacy, Dr. Palumbo has held a
number of positions. He was initially
recruited as an Assistant Professor and
rose through the academic ranks to full
professor in 1992. In addition, he has
served as an acting department chair and
a department chair of Pharmacy Practice
and Administrative Science. He also
served as Special Assistant to the Dean
and Interim Associate Dean for
Administration.
Dr. Palumbo co-founded the School
of Pharmacy’s Center on Drugs and
Public Policy in 1988 and served as its
Associate Director until 1998 when he
assumed the directorship of the Drug
Policy Research Center. The Center
currently has 10 faculty associates and
approximately 17 staff who collectively
are involved in several millions of dollars
of projects. The Center specializes in
providing credible, unbiased and
pragmatic solutions for government
agencies, the pharmaceutical industry,
professional organizations and private
businesses on public health issues and
practices involving medication use and
regulatory matters.
From 1988 to 1989, Dr. Palumbo took
a sabbatical from teaching to work at the
law firm of Hyman, Phelps & McNamara
practicing FDA law. He continues to act
as an expert witness in cases involving
FDA law. His research interests include
counterfeiting and drug importation,
specialty pharmaceuticals, drug use in the
elderly, direct to consumer advertising,
and the Medicare and Medicaid programs
and drug use. As for teaching at the law
school, Dr. Palumbo says, “It keeps me
on my toes.”
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T

he first time I heard about BIO
was in 1999, while I was still an
undergraduate studying biology at
Arizona State University (ASU). I was
taking a class on biotechnology and the
law through ASU’s law school. The
class focused on the intersection of
biotechnology, law, business, and health
care. My interest in biotechnology was a
huge motivating factor in my decision to go
to law school. Seven years later when I got
an email from Cindy Tippett, Director of
Health Law Externships at Maryland, about
an externship opportunity at BIO, there
was no doubt in my mind what to do. I
leapt at the opportunity to be an extern at
the place that had, in part, altered the
trajectory of my career from going into
medicine to studying law.
Externing at BIO through Maryland’s
Law & Health Care Program gave me the
unique opportunity to look at legal issues
through the lens of an industry organization.
I was able to earn credit toward a certificate
in health law, build my resume, and
network with professionals in health law and
policy whom I will likely work with in the
future.
While externing at BIO for four
months, I gained an appreciation for the
unique role of trade organizations. BIO
represents more than 1,100 biotechnology
companies, academic institutions, state
biotechnology centers and related
organizations across the U.S. and thirtyone other nations. BIO members are
involved in the research and development
of health care, agricultural, industrial and
environmental biotechnology products.

Because BIO’s membership is diverse,
there are departments for everything from
food and agriculture to intellectual
property and bioethics. I was impressed
with the open process that BIO used to
develop positions on issues that promote
the biotechnology industry and address
the needs of both small and large
companies.
Since I had worked for a few years
before entering law school, I enjoyed the
feeling of going to work again, even if it
was only Monday through Wednesday
nine to four. Taking the train to
Washington, D.C. was a thrill for me. I
grew up in Oklahoma, Indiana, and
Arizona, so D.C. always seemed like the
place—way over in the east—where
important people made big decisions.
Now that I’ve moved to the Maryland/
D.C. area, D.C. still has its allure, and I
feel fortunate to have had the
opportunity to become a part of the
action.
From the beginning, I was treated like
a member of BIO’s staff. I had my own
cubicle, computer, email, and phone. I
attended several meetings on a weekly
basis, and I valued the opportunity to
meet with BIO member company
representatives. Some of my first
impressions of BIO were very telling.
The pace at the office was fast because
BIO is constantly reacting to federal and
state legislation, member questions,
breakthroughs in science and technology,
and current events. I’m a fast walker, so I
liked the pace at BIO immediately.
During the first few weeks my
acronym vocabulary grew exponentially.
I knew some of the most common
acronyms in health care (e.g. FDA, CMS,
and HIPAA), but what I didn’t know was
all of the acronyms within the agencies,
especially CMS. Four months later, I was
ready for the acronym spelling bee! The

Cont. on page 16
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first time I went to a health care reform
and reimbursement meeting I was
astonished by who was at the table. The
big names in biotech that I regularly saw
in headlines were sitting at the table with
me! Meetings were always a learning
opportunity. I enjoyed fleshing out my
knowledge of emerging health care issues
along with professionals. For example, I
learned the details about Medicare Part D
implementation, the overlap between
Parts B and D, competitive acquisition
programs (CAP), drug compendia, and
the research exemption in patent law.
More importantly, I learned how new
federal regulations and state legislation
affect biotechnology companies in ways I
could not have predicted. By being
aware of companies' needs and imagining
how they would have to respond to rules
and state legislation, I learned how to
spot issues that would be important for
biotechnology companies.
While at BIO, I took advantage of the
D.C. location. I had fun attending Kaiser
Family Foundation media briefings on
health care issues where I learned about
national drug spending projections,
Medicare Part D implementation, and the
nation’s top health care objectives for the
year. One afternoon I attended a
welcome lunch for Representative Dan
Lipinski, Jr. (D-Ill.). To complement a
memo I drafted on the Federal Advisory
Committee Act, I covered meetings of
the Medicare Payment Advisory
Commission (MedPAC) and the
Secretary’s Advisory Committee on
Genetics, Health, and Society (SAGGHS).
I was amazed by how many meetings and
events occur every day in D.C. that are
related to health care law. An
unseasonably cold and windy day was
made a lot brighter by my very first trip
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Second year law student Linda Souter (left), with BIO supervising attorneys
Jayson Slotnik and India Valentine who graduated from Maryland Law in
2001 and 1998 respectively.

to the Capitol for a Massachusetts
Biotech and National Venture Capital
Association briefing. I was with BIO staff
who had been inside the Capitol many
times, so I tried to control my
excitement; however, it was probably
quite obvious that I was a first-timer
when I was the only person with eyes
glued to the ceiling in the Brumidi
corridors! Nevertheless, I saw the
rotunda and felt like a real D.C. extern.
To my delight, I had the opportunity to
return to the Hill for a second time for
BIO’s Fly-In, which involved member
companies meeting state leaders on the
Hill and discussing biotech issues in their
states.
Much of my BIO experience felt like
being at a fantastic health law summer
camp. Instead of learning how to make
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lanyards and canoes, I had a mini course
in administrative law and learned how to
navigate the waters of Medicare Part D.
There were always lots of meetings,
events, and activities to take part in at
BIO or in D.C., but not enough time to
do them all. While at BIO, I developed
a working knowledge of Medicare and
Medicaid. I developed a new interest in
reimbursement issues and a respect for
how important they are in the health care
economy. Externing at BIO provided me
with valuable lessons about health care
and biotechnology that I will certainly
use in the future. I’m looking forward to
an exciting career in health care law after
I graduate in May 2006!
Linda Souter
University of Maryland
School of Law, ‘06
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Congratulations to second-year law
student Brooke Courtney and fourth-year
evening student Drew Smith for their
achievement in the annual Epstein,
Becker & Green Health Law Writing
Competition. Brooke’s paper, “Is
Obesity Really the Next Tobacco?
Lessons from Tobacco for Obesity
Litigation,” and Drew’s paper,
“Maryland’s Medical Malpractice Crisis:
The Real Diagnosis,” were selected as
being among the top 20% of papers
entered in the competition and are being
considered for publication in the Annals
of Health Law.

Brooke Courtney (2D) and Drew Smith (4E)
Cori Annapolen, a second-year law
student, also deserves kudos for her first
place prize in the student writing
competition held at the Second World
Conference on Nonsmokers’ Rights.
Cori’s paper, "Maternal Smoking During
Pregnancy: the Harmful Effects on the
Exposed Fetus and the Proposed Legal
Implications for the Mother’s Actions,"
prevailed over 19 other finalists. The
award included $5,000 and publication in
the Virginia Journal of Social Policy and the
Law.

Second year law student Mikaela
Rossmann came to law school to pursue
the certificate of concentration in health
law. This semester she is externing at
Washington Hospital Center, where she
splits her time between the General
Counsel’s Office and the Bioethics
Office. In addition to her busy work and
class schedule, Mikaela finds time to run
her own business. The following story
ran in The Daily Record last December.

T

o deal with the stress of her first
year at law school, Mikaela
Rossman started baking. And
baking. And baking some more.
“I didn’t want to eat it all so I started
taking it into school and giving it away,”
she said. Pretty soon, orders for cakes
and other desserts started pouring in,
giving rise to Torts and Tarts.
A year later, Rossman’s novelty cakes
command prices of $35 to $125 each.
Most of her business comes by word of
mouth, and the holiday season has been
particularly busy for her: She’s been
baking practically nonstop since her last
exam on December 15.
But Rossman expects business to pick
up even more in the New Year as she
begins selling her signature gourmet desserts
through the Hickory Ridge Grill, a Greek
restaurant in Columbia. Her cakes, sold
whole or by the slice, will supplement the
restaurant’s otherwise limited two-dessert
menu.
Now a second-year student at the
University of Maryland School of Law,
Rossman said she’s been looking to
expand Torts and Tarts for the past few
months, and is seeking help to
incorporate in the near future.
“I could figure it out but I don’t have
the time between law school and the
baking to do it,” said Rossman, who will
begin an internship with the general
counsel’s office at Washington Hospital
Center in January.
She developed an interest in health
care law and policy after undergoing
treatment for aggressive fibromatosis, a
type of cancer.

“Through that experience, just being
in the health care system, you really
realize how helpless you are,” she said.
But for baking guidance, Rossman
sought advice from Warren Brown —
not the famed Baltimore criminal defense
attorney, but a successful governmentlawyer-turned-baker in Washington.
Brown left his job as a litigator with the
Department of Health and Human
Services in 2002 to open Cakelove, a
bakery in Adams Morgan. His journey
from law to flour has been featured in
The Washington Post and People magazine,
as well as on Oprah Winfrey’s show.
Like Brown, Rossman said she’s been
baking since childhood. “Law is my
career, baking is my passion,” she notes
on her web site.
“I grew up in a house where there was
a lot of baking,” Rossman said, standing
in her Columbia kitchen with her hands
covered in batter. “My mother is an
amazing baker. People have been telling
her for years that she should quit her job
and go into baking.”
Rossman has no plans to abandon the
law for baking, although eventually she
would like to find some way to combine
the two. “I would love to find a lawyer
or a small law firm that would want to
expand as a bakery, too,” she said.
December 27, 2004
By ALISA BRALOVE,
Daily Record Legal Affairs Writer
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On March 30, 2005, SHLO held its Health Law Networking Dinner. More than 35 attorneys from different areas
of health law attended. This annual event gives students the opportunity to mingle with practicing attorneys in an
informal setting and ask about all things related to careers in health law.

(Left to right) Monika Ras (2D); Virginia Evans, Chief of the Civil
Division, U.S. Attorney’s Office; and Rachael Melby (3D).

(Left to right) Jennifer Martin (1D), Kristen King
(1D) and Benjamin Cohen, Attorney, Centers for
Medicare and Medicaid Services, Office of Hearings.

(Left to right) Michelle Saffan (1D); Melissa Sviatko (1D); Jeff Pecore, Pecore & Doherty;
Jaime Doherty, Pecore & Doherty; and Mindy Caplan (‘01), Kramon & Graham.
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Kristin Cline (2D) and Jason Weinstock, Attorney General’s
Office, Medicaid Fraud Unit.

(Left to right) Kelly Walsh (1D); Irv Cohen, Fulbright
& Jaworski; and Meaghan Shepard (1D).

Christine Morse (‘99), Ober Kaler, and
Mona Shah (2D).
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Focus on Drugs & Health Law
Cont. from page 4
Attorney General to prevent enforcement
or application of the directive. A U.S.
District Court judge issued a permanent
injunction preventing implementation of
the directive. Judge Robert Jones ruled
that the CSA was not intended to overrule
a state’s decision on what constitutes
“legitimate medical practice” and found
that the Attorney General and the DEA
went beyond their authority in trying to
control physicians acting under the DDA.
The Ninth Circuit ordered a continuation
of the injunction. The case is now on
appeal to the Supreme Court. (Visiting
Prof. Dan Gilman, is current writing an article
about the case. See article on Faculty
Scholarship, p. 13, for more on his
perspective.)
Many other drugs are also subject to
abuse and addiction. These range from
steroids to heroin and cocaine. Often
individuals with a history of drug abuse or
who are in drug treatment programs face
discrimination in obtaining housing,
employment and treatment. In Prof. Ellen

Weber’s Drug Policy and Practice Clinic, students
examine a range of public health and civil rights
strategies to assist persons with histories of drug
and alcohol dependence and the programs that
serve them. Examples of the legal work students
have performed in the past include presenting
testimony and conducting advocacy to address
discriminatory zoning barriers to the
establishment of treatment services; representing
individual clients in employment discrimination
matters; conducting administrative and legislative
advocacy to address the denial of drug treatment
to individuals detained in the Baltimore City
Detention Center; and advising organizational
clients on the implementation of the Health
Insurance Portability and Accountability Act
(HIPAA) health privacy regulations. Also,
students in Prof. Kathleen Dachille’s Tobacco
Control Clinic have worked on initiatives to
assist individuals who are addicted to tobacco
products. This legislative session, the clinic
students were instrumental in the passage of a bill
that will require health insurers in Maryland that
provide prescription benefits to cover prescription
drugs used to assist in tobacco use cessation.
Currently, buproprion, known as Zyban, is
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commonly used to assist smokers, and there are
at least two other drugs under FDA review that
are designed to assist in tobacco use cessation.
The clinic students drafted the original bill for
Delegate Dan Morhaim, testified in support of
the bill in the House Health and Government
Operations Committee and the Senate Finance
Committee, and drafted amendments to the bill
necessary to achieve passage.
Notes
1

Consumer Project on Technology,
Recent Health-Related Compulsory Licenses
and Disputes, http://cptech.org/ip/
health/cl/recent-examples.html (Apr. 25,
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2
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3
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4
FDA, FDA and the Drug Development
Process: How the Agency Ensures that Drugs
are Safe and Effective, http://www.fda.gov/
opacom/factsheets/justthefacts/
17drgdev.html (Apr. 25, 2005).
5
S. Waxman, Lawsuits Blame Women’s
Deaths on Unregulated Herbal Products, THE
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